The first clinical trial to investigate the effect of a standardized physical therapy treatment, directed to the cervical spine, on tinnitus is being conducted at the University of Antwerp.
Auris Medical Holding AG —the developer of treatments for acute inner ear tinnitus (AM-101) and acute inner ear hearing loss (AM-111) by way of intratympanic injection—announced on August 6 pricing of its IPO. The company’s common shares have been approved for listing on the NASDAQ Global Market and are expected to begin trading under the ticker symbol “EARS”.
Loyola University surgeon says athletes who play football and other contact sports may be at risk for hearing damage and tinnitus.
Patients with tinnitus process emotions differently in the brain from those with normal hearing, researchers report in the journal Brain Research.
Neuromonics, a manufacturer and distributor of tinnitus treatment devices, has signed a reseller agreement with AuDConnex.
Researchers at The University of Western Australia have shown changes in a part of the brain previously not known to be involved in tinnitus generation.
The new findings suggest that noise-induced hearing loss has another very important component beyond just hair cells: the loss of cochlear nerve fibers.
In Part 4 of this 5-part series, our roundtable takes on the topics of marketing and outreach to physicians, changing attitudes about hearing aids in younger patients, and a greater willingness to try new technology.
Researchers supported by the National Institutes of Health (NIH) are launching a clinical trial to test a device that uses nervous system stimuli to rewire parts of the brain, in hopes of significantly reducing or removing tinnitus.
Research reveals why hearing loss is correlated with auditory signals failing to get transmitted along the auditory nerve.